NNVC - NanoViricides progressing well with new Covid study

(NewsDirect)

Proactive research analyst John Savinspeaks to Thomas Warner after publishing a research note about thelatest Covid trial from development-stage antiviral companyNanoViricides (NYSE-A:NNVC).

Theongoing NV-CoV-2 Phase Ia clinical study is a key milestone in thedevelopment of Nanoviricides' (NV) novel and innovative anti-virustherapy, NV-CoV-2 uses a sophisticated polymer (NV-387) as the activeingredient to trap and disrupt viruses in the blood.

The polymer is integrated into the productwhich has now entered a clinical trial in India. With 26 out of 36non-COVID volunteers completing the single dose stage and 17 advancingto the multi-dose phase, the trial has achieved a significantmilestone.

The absence of safetyconcerns is noteworthy. The trial examines two administration routes:a gummy and a syrup. Crucially, the trial aims to determine bloodlevels and safety, laying the foundation for potential efficacy.

A subsequent trial will involve 36mild-to-moderate COVID-19 patients. Despite the emergence of new virusstrains, NanoViricides remains optimistic, as the env 387 polymer mayenhance binding effectiveness. Click the provided link to access JohnSavin's comprehensive research on this excitingdevelopment.

Contact Details

ProactiveInvestors

+1 604-688-8158

na-editorial@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.